Lonza News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.11.24	Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites (EQS Group)
22.10.24	Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates (EQS Group)
03.10.24	Lonza Nominates David Meline as Independent Board Member (EQS Group)
01.10.24	Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche (EQS Group)
24.09.24	Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) (EQS Group)
28.08.24	Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds (EQS Group)
25.07.24	Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members (EQS Group)
01.07.24	Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand (EQS Group)
08.05.24	Lonza gibt Ergebnisse der Generalversammlung 2024 bekannt – Alle Anträge des Verwaltungsrats wurden genehmigt (EQS Group)
08.05.24	Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved (EQS Group)
17.04.24	Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon (EQS Group)
06.11.23	Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds (EQS Group)
13.10.23	Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer (EQS Group)
01.06.23	Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering (EQS Group)
05.05.23	Lonza gibt Ergebnisse der Generalversammlung 2023 bekannt Alle Anträge des Verwaltungsrats wurden angenommen (EQS Group)
05.05.23	Lonza Announces Results of the 2023 Annual General Meeting All Motions Proposed by Board of Directors Accepted (EQS Group)
20.04.23	Lonza Increases Straight Bond by CHF 150 Million (EQS Group)
31.03.23	Lonza Launches Share Buyback Program of up to CHF 2 Billion (EQS Group)
29.03.23	Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH) (EQS Group)
16.02.23	Lonza Completes Expansion of Conjugation Facility in Visp (CH) (EQS Group)
08.02.23	Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon (EQS Group)
01.11.22	Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine (EQS Group)
12.09.22	Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division (EQS Group)
06.09.22	Lonza and Touchlight collaborate on end-to-end mRNA offering (EQS Group)
01.07.22	Maria Soler Nunez appointed as Head, Group Operations (EQS Group)
29.04.21	Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp (Tensid)
23.04.21	Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp (Tensid)
25.03.21	Lonza Publishes Invitation to the 2021 Annual General Meeting and 2020 Annual and Sustainability Reports (Tensid)
08.02.21	Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven (Tensid)
27.01.21	Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business (Tensid)
19.01.21	NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms (Tensid)
02.12.20	Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates (Tensid)
10.11.20	Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID, its Single-Dose Intranasal Vaccine Candidate for COVID-19 (Tensid)
02.11.20	Lonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux (Tensid)
30.10.20	Lonza Announces Agreement to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination (Tensid)
22.10.20	Lonza Expands Its Capsule Manufacturing Capacity (Tensid)
15.10.20	Investor Update Details Business Structure, Divisional Dynamics, New External Reporting and Guidance (Tensid)
08.09.20	Sheba Medical Center Treats First Patient with CAR-T Cell Immunotherapy Manufactured Using the Lonza Cocoon® Platform (Tensid)
04.08.20	Lonza Expands Microbial Capacity and Extends Long-term Partnership with Servier for L-asparaginase API Manufacturing (Tensid)
30.07.20	Lonza Disinfectant Ingredients Secure U.S. EPA Approval for Surface Use Against SARS-CoV-2 Virus (Tensid)
27.07.20	Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases (Tensid)
24.07.20	Lonza im ersten Halbjahr 2020 mit starkem Umsatzwachstum und Margenverbesserung, getragen vom Pharma Biotech-Geschäft (Tensid)
30.06.20	Sven Abend Leaves Lonza to Take CEO Position in Germany (Tensid)
05.06.20	Lonza Appoints N ew Chief Executive Officer (Tensid)
18.05.20	Moncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group (Tensid)
01.05.20	Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus (Tensid)
17.04.20	Lonza Reports Solid Q1 2020 Performance, with Segments Continuing to Deliver Essential Services for Pharma and Disinfection (Tensid)
20.03.20	Lonza Publishes 2020 AGM Invitation (Tensid)
17.03.20	Lonza Publishes its Online Annual & Sustainability Reports 2019 (Tensid)
11.03.20	Lonza Group Strengthens its Executive Committee with the Appointment of New CHRO (Tensid)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

10:02		SMI-Papier Lonza-Aktie: So viel Verlust hätte ein Investment in Lonza von vor 3 Jahren eingebracht
09:28		Zurückhaltung in Zürich: SMI zum Handelsstart im Minus
20.11.24		Anleger in Zürich halten sich zurück: SMI letztendlich leichter
20.11.24		SLI aktuell: SLI liegt zum Start des Mittwochshandels im Plus
20.11.24		Zuversicht in Zürich: SMI zeigt sich zum Handelsstart fester
19.11.24		Zurückhaltung in Zürich: SMI zum Ende des Dienstagshandels im Minus
19.11.24		Börse Zürich: SLI fällt zum Ende des Dienstagshandels
19.11.24		Börse Zürich: SMI sackt ab

10:02

SMI-Papier Lonza-Aktie: So viel Verlust hätte ein Investment in Lonza von vor 3 Jahren eingebracht

09:28

Zurückhaltung in Zürich: SMI zum Handelsstart im Minus

20.11.24

Anleger in Zürich halten sich zurück: SMI letztendlich leichter

20.11.24

SLI aktuell: SLI liegt zum Start des Mittwochshandels im Plus

20.11.24

Zuversicht in Zürich: SMI zeigt sich zum Handelsstart fester

19.11.24

Zurückhaltung in Zürich: SMI zum Ende des Dienstagshandels im Minus

19.11.24

Börse Zürich: SLI fällt zum Ende des Dienstagshandels

19.11.24

Börse Zürich: SMI sackt ab

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Zurich Insur Gr	547.20	3.05 %	K V
Logitech Intl	70.02	2.22 %	K V
Givaudan	3’927.00	1.66 %	K V
Swiss Re	127.20	0.99 %	K V
Sonova Hldg	305.20	0.59 %	K V
Kuehne+Nagel Int	207.30	-0.43 %	K V
Sika	228.60	-0.52 %	K V
Holcim	89.54	-0.60 %	K V
Nestle	75.98	-0.71 %	K V
CieFinRichemont	116.90	-1.43 %	K V

Nachrichten zu Lonza AG (N)

Aktien Top/Flop

Lonza Peer Group Nachrichten

Meistgelesene Nachrichten